Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of HLX10 monotherapy in previously treated unresectable or metastatic MSI-H/dMMR solid tumors
CTR20190719Phase 2Terminated
- Sponsor
- HyBioPharma
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in Nonhematologic neoplasms, mismatch repair deficient solid tumor, sponsored by HyBioPharma. Started Aug 2019; status: terminated.
02
Drugs
serplulimab
03
Conditions
Nonhematologic neoplasmsmismatch repair deficient solid tumor
Beyond the preview
Go deeper on CTR20190719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190719.